Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

Muscarinic pathways are a new addition to the treatment arsenal. Credit: jiris via Shutterstock. On 26 September 2024, Cobenfy (KarXT) gained US Food and Drug Administration (FDA) approval as the ...

Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine. Learn why RVPH stock offers potential ...

According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...

Despite previous low sentiment towards Neurocrine’s muscarinic program, this competitive failure provides a chance for a larger market opportunity, assuming Neurocrine successfully navigates the ...

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

An estimated one-quarter to one-third of people with schizophrenia have symptoms that don’t improve with traditional ...

J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA ...